Table 1.
Completed and ongoing trials of MSCs in heart disease.
Clinicaltrials.gov identifier | Disease type | Study design | Route of delivery | Endpoint | Enrolled number | Type of MSCs | Status |
---|---|---|---|---|---|---|---|
NCT0011445260 | Acute MI | Randomized; parallel assigned; phase I | Intravenous injection | Adverse event rates | 53 | Adult hMSCs | Completed |
NCT03902067 | Acute MI | Randomized; parallel assigned; phase I | Injection into blood vessels through an administration catheter | Safety, LVEF | 40 | UC-MSCs | Not yet recruiting |
NCT03533153 | MI | Randomized; parallel assigned; phase I/ II | Intravenous injection | Heart function; infarct size | 90 | Clinical-grade WJ-MSCs | Not yet recruiting |
NCT0232347761 | Chronic ischemic cardiomyopathy | Randomized; parallel assigned; single; phase I/ II | Intramyocardial injection | LVEF; LVED; LVES | 79 | UC-MSCs | Unknown |
NCT02503280 | Chronic ischemic left ventricular dysfunction | Randomized; parallel assigned; single; phase I/ II | Transendocardial injection | Safety; cardiac function | 55 | hMSCs | Not yet recruiting |
NCT01652209 | Acute MI | Randomized; parallel assigned; open label; phase III | Intramyocardial injection | Efficacy and safety | 135 | BM-MSCs | Recruiting |
NCT02013674 | Chronic ischemic left ventricular dysfunction | Randomized; parallel assigned; phase II | Injected through BioCardia helical infusion system | Safety; efficacy assessment | 30 | Allogeneic hMSCs | Unknown |
NCT0246738785 | Nonischemic heart failure | Single-blind, randomized; phase II | Intravenously injection | 6-minute walking distance; LVEF | 22 | BM- MSCs | Completed |
NCT0173977762 | Chronic stable heart failure | Randomized controlled trial; phase I/ II | Intracoronary injection | Safety, NYHA; LVEF | 22 | UC-MSCs | Completed |
NCT0129132986 | ST-elevation MI | Randomized; parallel assigned; phase II | Intracoronary injection | Safety; LVEF | 160 | Umbilical WJ-MSCs | Completed |
NCT00883727 | ST-elevation acute MI | Randomized; parallel assigned; triple; phase I/ II | Intravenous injection | Regional myocardial perfusion and infarct size | 20 | Adult allogenic MSCs | Completed |
NCT0139210587 | Acute MI | Randomized; parallel assigned; open label; phase II/ III | Intracoronary injection | LVEF | 80 | BM-hMSCs | Completed |
MI myocardial infarction, NYHA New York Heart Association functional class, LVEF left ventricular ejection fraction, LVED left ventricular end diastolic diameter, LVES left ventricular systolic diameter.